176 related articles for article (PubMed ID: 16793238)
1. Antipsychotic medication and cognitive function in schizophrenia.
Hori H; Noguchi H; Hashimoto R; Nakabayashi T; Omori M; Takahashi S; Tsukue R; Anami K; Hirabayashi N; Harada S; Saitoh O; Iwase M; Kajimoto O; Takeda M; Okabe S; Kunugi H
Schizophr Res; 2006 Sep; 86(1-3):138-46. PubMed ID: 16793238
[TBL] [Abstract][Full Text] [Related]
2. Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia.
El-Missiry A; Elbatrawy A; El Missiry M; Moneim DA; Ali R; Essawy H
J Psychiatr Res; 2015 Nov; 70():106-12. PubMed ID: 26424429
[TBL] [Abstract][Full Text] [Related]
3. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
[TBL] [Abstract][Full Text] [Related]
4. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
5. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia.
Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745
[TBL] [Abstract][Full Text] [Related]
6. The effect of verbalization strategy on Wisconsin Card Sorting Test performance in schizophrenic patients receiving classical or atypical antipsychotics.
Rossi A; Daneluzzo E; Tomassini A; Struglia F; Cavallaro R; Smeraldi E; Stratta P
BMC Psychiatry; 2006 Jan; 6():3. PubMed ID: 16438712
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia.
Gold S; Arndt S; Nopoulos P; O'Leary DS; Andreasen NC
Am J Psychiatry; 1999 Sep; 156(9):1342-8. PubMed ID: 10484943
[TBL] [Abstract][Full Text] [Related]
8. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
Rémillard S; Pourcher E; Cohen H
Schizophr Res; 2005 Dec; 80(1):99-106. PubMed ID: 16162401
[TBL] [Abstract][Full Text] [Related]
9. Profiling cognitive impairment in treatment-resistant schizophrenia patients.
Frydecka D; Beszłej JA; Gościmski P; Kiejna A; Misiak B
Psychiatry Res; 2016 Jan; 235():133-8. PubMed ID: 26706131
[TBL] [Abstract][Full Text] [Related]
10. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.
Yi Z; Fan X; Wang J; Liu D; Freudenreich O; Goff D; Henderson DC
Psychiatry Res; 2012 Dec; 200(2-3):79-82. PubMed ID: 22727707
[TBL] [Abstract][Full Text] [Related]
12. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients.
Fujii DE; Ahmed I; Jokumsen M; Compton JM
J Neuropsychiatry Clin Neurosci; 1997; 9(2):240-5. PubMed ID: 9144103
[TBL] [Abstract][Full Text] [Related]
13. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia.
Sumiyoshi T; Jayathilake K; Meltzer HY
Schizophr Res; 2003 Jan; 59(1):7-16. PubMed ID: 12413636
[TBL] [Abstract][Full Text] [Related]
14. Impairment of motor dexterity in schizophrenia assessed by a novel finger movement test.
Midorikawa A; Hashimoto R; Noguchi H; Saitoh O; Kunugi H; Nakamura K
Psychiatry Res; 2008 Jun; 159(3):281-9. PubMed ID: 18448171
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds.
Weickert TW; Goldberg TE; Marenco S; Bigelow LB; Egan MF; Weinberger DR
Neuropsychopharmacology; 2003 Aug; 28(8):1491-500. PubMed ID: 12799617
[TBL] [Abstract][Full Text] [Related]
16. Association between attitude toward medication and neurocognitive function in schizophrenia.
Kim SW; Shin IS; Kim JM; Yang SJ; Shin HY; Yoon JS
Clin Neuropharmacol; 2006; 29(4):197-205. PubMed ID: 16855421
[TBL] [Abstract][Full Text] [Related]
17. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects.
Altshuler LL; Ventura J; van Gorp WG; Green MF; Theberge DC; Mintz J
Biol Psychiatry; 2004 Oct; 56(8):560-9. PubMed ID: 15476685
[TBL] [Abstract][Full Text] [Related]
18. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
[TBL] [Abstract][Full Text] [Related]
19. The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
Good KP; Rabinowitz J; Whitehorn D; Harvey PD; DeSmedt G; Kopala LC
Schizophr Res; 2004 May; 68(1):11-9. PubMed ID: 15037335
[TBL] [Abstract][Full Text] [Related]
20. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia.
Daban C; Amado I; Bourdel MC; Loo H; Olié JP; Poirier MF; Krebs MO
J Psychiatr Res; 2005 Jul; 39(4):391-8. PubMed ID: 15804389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
